MCL1 and diffuse large B-cell lymphoma: Additional studies will be needed to determine if increased doses of BIM SAHBA, as used in Figure 4D, or various treatment times would adequately remove BIM from DLBCL with larger amounts of MCL-1 following treatment with ABT-737 or ultimately stabilize MCL-1 protein levels as do newly introduced high-affinity small molecule MCL-1 inhibitors [6, 50].